Alexion Pharmaceuticals (NASDAQ:ALXN) has tumbled 7.68% during the past week and has dropped 12.15% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 6.57%. Alexion Pharmaceuticals (NASDAQ:ALXN) has underperformed the index by 12.95% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Alexion Pharmaceuticals (NASDAQ:ALXN): The stock opened at $126.98 on Friday but the bulls could not build on the opening and the stock topped out at $127.49 for the day. The stock traded down to $124.80 during the day, due to lack of any buying support eventually closed down at $125.20 with a loss of -1.80% for the day. The stock had closed at $127.49 on the previous day. The total traded volume was 3,526,557 shares.
The company shares have dropped -33.49% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $208.88 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $141.96 and the 200 Day Moving Average price is recorded at $152.50.
On the companys insider trading activities, Moriarty John B, officer (EVP & General Counsel) of Alexion Pharmaceuticals Inc, unloaded 918 shares at an average price of $135.72 on June 13, 2016. The total amount of the transaction was worth $124,591, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Morgan Stanley, maintains their rating on the shares of Alexion Pharmaceuticals (NASDAQ:ALXN). Morgan Stanley has a Overweight rating on the shares. As per the latest research report, the brokerage house lowers the price target to $189 per share from a prior target of $203. The rating by the firm was issued on June 7, 2016. Currently the company Insiders own 4.41% of Alexion Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -2.06% . Institutional Investors own 98.92% of Alexion Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -2.25%.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.